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Strengths and limitations of this study
 ► Use of national aggregate data gives a comprehen-
sive picture of the country.
 ► The ecological design of the study may result in 
‘ecological fallacy’.
 ► Despite use of aggregate data, findings are similar 
to studies using individual data.
 ► Use of tuberculosis (TB) case notifications does not 
account for undiagnosed TB cases.
 ► All factors contributing to declining TB case notifica-
tions are not accounted for.
AbStrACt
Objectives Antiretroviral therapy (ART) and isoniazid 
preventive therapy (IPT) are known to have a tuberculosis 
(TB) protective effect at the individual level among people 
living with HIV (PLHIV). In Zimbabwe where TB is driven 
by HIV infection, we have assessed whether there is a 
population- level association between IPT and ART scale- up 
and annual TB case notification rates (CNRs) from 2000 to 
2018.
Design Ecological study using aggregate national data.
Setting Annual aggregate national data on TB case 
notification rates (stratified by TB category and type of 
disease), numbers (and proportions) of PLHIV in ART care 
and of these, numbers (and proportions) ever commenced 
on IPT.
results ART coverage in the public sector increased from 
<1% (8400 PLHIV) in 2004 to ~88% (>1.1 million PLHIV 
patients) by December 2018, while IPT coverage among 
PLHIV in ART care increased from <1% (98 PLHIV) in 2012 
to ~33% (373 917 PLHIV) by December 2018. These 
HIV- related interventions were associated with significant 
declines in TB CNRs: between the highest CNR prior to 
national roll- out of ART (in 2004) to the lowest recorded 
CNR after national IPT roll- out from 2012, these were (1) 
for all TB case (510 to 173 cases/100 000 population; 
66% decline, p<0.001); (2) for those with new TB (501 to 
159 cases/100 000 population; 68% decline, p<0.001) 
and (3) for those with new clinically diagnosed PTB (284 to 
63 cases/100 000 population; 77.8% decline, p<0.001).
Conclusions This study shows the population- level 
impact of the continued scale- up of ART among PLHIV and 
the national roll- out of IPT among those in ART care in 
reducing TB, particularly clinically diagnosed TB which is 
largely associated with HIV. There are further opportunities 
for continued mitigation of TB with increasing coverage of 
ART and in particular IPT which still has a low coverage.
bACkgrOunD
Tuberculosis (TB), one of the oldest bacterial 
infections known to mankind and the HIV 
infection are a deadly combination. While 
the lifetime risk of developing active TB 
disease among people with latent TB infec-
tion (LTBI) is 5%–15%,1 those with HIV have 
a 5%–15% annual risk of acquiring active TB 
disease.2 The TB epidemic in sub- Saharan 
Africa is largely driven by the HIV epidemic 
which disproportionately affects this region. 
About 70% of the 36.9 million people living 
with HIV (PLHIV) globally live in sub- Saharan 
Africa, of whom 76% are found in the eastern 
and southern regions. This is despite the fact 
that sub- Saharan Africa contributes only 14% 
of the world’s population.3
Of the estimated 10 million people who 
developed TB disease in 2017, 9% were 
PLHIV of whom 72% lived in the Africa 
region.4 Among those with TB and HIV coin-
fection, the majority (84%) were from the 
Africa region.4 Despite this large prevalence, 
there has been a 44% decline in the number 
of HIV/TB associated deaths since 2000. This 
is largely attributed to an increased uptake 
of antiretroviral therapy (ART) among those 
with HIV- associated TB. Coverage of ART in 
Africa has more than doubled from 35% in 
2005 to 84% in 2017.4 5
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ART is associated with a 67% reduced risk of developing 
active TB disease among PLHIV6 and an even further 
reduction in recurrent TB.7 ART has also been shown to 
reduce the population incidence of TB by between 27% 
and 80%.8 9 However, despite ART having a TB protec-
tive effect at the individual level, which has further been 
shown to positively correlate with higher updated CD4 
cell counts,10 11 the incidence of TB still remains higher 
in the HIV- positive population compared with the HIV- 
negative population.11
To further mitigate TB in this high- risk group, isoni-
azid preventive therapy (IPT) has also been found to be 
effective in reducing the incidence of TB and death from 
TB among PLHIV with further reductions in TB risk of 
up to 90% among those receiving both IPT and ART.12–14 
This has led the WHO to recommend initiation of IPT 
among PLHIV enrolled in ART care in whom TB has 
been excluded using a clinical TB screening algorithm.15
Zimbabwe is one of the sub- Saharan African countries 
with a largely HIV- driven TB epidemic and is among the 
14 countries globally with a triple burden of TB, TB/
HIV and multidrug resistant TB.4 A previous publication 
from Zimbabwe evaluating a 14- year period from 2000 to 
2013 showed that with increasing ART coverage since its 
inception in the public sector in 2004, annual TB case 
notification rates more than halved for all forms of TB. 
Furthermore, the largest declines were among those with 
recurrent TB (53%), new smear- negative pulmonary 
TB (58%) and extrapulmonary TB (58%).16 Zimbabwe 
also adopted WHO guidance on provision of IPT among 
PLHIV in 2011. There was an initial pilot phase in 10 
health facilities where the delivery of IPT was found to 
be feasible, and this was followed by nationwide roll- out 
to most of the public health facilities in the country.17 18 
The country has also adopted the ‘HIV treat all’ approach 
from mid-2016 where those who test HIV positive are 
immediately eligible for ART initiation regardless of their 
CD4 cell count or WHO clinical staging.
We hypothesise that the nationwide scale- up of IPT; 
the continued increase in ART coverage and the earlier 
initiation of ART have all had a population impact on 
reducing TB incidence in Zimbabwe, translating to 
further declines in TB case notification rates. Currently, 
there are no reports or published papers comparing the 
national scale- up of IPT and ART with national TB case 
notification rates. We therefore describe in this paper the 
association between IPT and ART scale- up and annual TB 
case notification rates in Zimbabwe from 2000 to 2018.
MethODS
Study design
This was an ecological study design using aggregate 
programme data to analyse for trends and associations.
Setting
Zimbabwe is a developing country in Southern African 
with a population of 13 million19 according to latest 
census data. There is a gross national index per capita 
of US$86020 and 72.3% of the population live below the 
national poverty line.20 The country has a high HIV prev-
alence rate of 15%, and the total number of adults and 
children living with HIV was estimated at 1.3 million in 
2018 according to the Joint United Nations Programme 
on HIV/AIDS (UNAIDS).21
The National Art Programme in Zimbabwe
Antiretroviral drugs were first offered in public health 
facilities in 2004 under the National ART Programme at 
five central level hospitals. As of December 2018, ART 
was available at 1604 (93%) out of 1722 health facilities 
nationwide.22 Since the inception of the ART programme 
in 2004, the criteria for initiating ART among adults has 
shifted from a CD4 cell count threshold of <200 cells/mL 
until 2010, to <350 cells/mL from 2011 to 2013 and to 
<500 cells/mL from 2014 in accordance with WHO guide-
lines.23–25 Those with advanced HIV disease have always 
been eligible for ART regardless of CD4 cell count.
Towards the end of 2013, there was a shift towards 
universal eligibility for lifelong ART in Zimbabwe. This 
started under option B+ when all HIV- infected pregnant 
and breastfeeding women were initiated on ART irrespec-
tive of their CD4 counts or WHO staging. Over this same 
period, ART regimens became simpler, less toxic and with 
a reduced pill burden given the transition to one pill per 
day fixed- dose combination regimens. From mid-2016 
onwards, the country started implementing the ‘HIV treat 
all’ approach whereby all patients who were diagnosed 
HIV positive are immediately eligible for ART initiation 
regardless of CD4 cell count or WHO clinical staging.
Intensive TB case finding, IPT initiation and enrolment in art care
All confirmed PLHIV in Zimbabwe are enrolled at 
ART clinics to receive HIV treatment and care services. 
According to Zimbabwe’s national IPT guidelines, all 
PLHIV should be screened for active TB at every clinic 
visit or every encounter with a health worker using the 
WHO recommended four- symptom TB screening check-
list.26 If PLHIV present with any of the four symptoms 
(cough of any duration, night sweats, weight loss and 
fever), they are considered as presumptive TB cases and 
have their sputum specimens collected for investigation 
by smear microscopy or Xpert MTB/Rif assay (Cepheid, 
Sunnyvale, California, USA) . Those who are negative on 
smear microscopy or Xpert MTB/Rif assay or both and 
who have no other symptoms or signs of extrapulmo-
nary or smear- negative PTB, including chest radiography 
if necessary, are not diagnosed with active TB and are 
potentially eligible for IPT.
IPT eligibility has changed over time. At the start of the 
programme in 2011, all patients enrolled in HIV care were 
eligible for IPT regardless of ART status, provided active 
TB was excluded. Since the national ART programme 
moved towards an ‘HIV treat all’ approach, all PLHIV in 
pre- ART care were recalled to health facilities for ART 
initiation and were prioritised for ART care first and then 
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initiated on IPT. All those eligible for IPT are started on a 
6- month daily oral dose of isoniazid (5 mg/kg body weight 
for adults or 10 mg/kg body weight for children) plus a 
daily low dose of pyridoxine (25 mg/day). To prevent 
unnecessary visits to health facilities, resupplies of IPT 
and pyridoxine are synchronised to ARV resupplies until 
completion of TB preventive treatment. During clinic 
visits, patients are assessed through self- reporting and 
pill counts for adherence, and they are also screened for 
TB. Patients found to have developed active TB disease 
are discontinued from IPT and are subsequently treated 
for TB according to national TB guidelines.26 By the end 
of June 2019, there were 1280 (74%) out of 1722 public 
health facilities offering IPT in addition to ART across the 
country’s 10 provinces (National ART Programme data).
The National TB Programme in Zimbabwe
Zimbabwe like other countries with a high prevalence of 
TB has a well- established WHO recommended directly 
observed treatment short course (DOTS)27 national 
TB programme (NTP), whereby TB treatment services 
are integrated with general health services at all health 
facilities countrywide. This DOTS model consists of a 
centralised and prioritised system of TB monitoring, 
recording and training of TB case management, and there 
is also a standardised recording and reporting system that 
allows assessment of treatment results. National TB treat-
ment outcomes are recorded and reported in line with 
WHO guidelines and are classified as treatment success 
(cured plus treatment completed), loss to follow- up 
(LTFU), died, transferred out or not evaluated and failed 
treatment.
Patients with TB are classified as either new or previ-
ously treated TB cases, whereby new cases are those 
who have never received anti- TB treatment or have 
previously received anti- TB drugs for <30 days, while 
previously treated TB cases are those patients who have 
previously received anti- TB drugs for >1 month. Prior 
to 2013, new TB cases were divided into smear- positive 
pulmonary (PTB), smear- negative PTB or extrapulmo-
nary TB (EPTB) cases, while retreatment patients with 
TB were categorised as follows: (1) relapse cases, (2) 
treatment after failure, (3) treatment after LTFU or (4) 
‘retreatment other’ based on smear microscopy. However 
from 2013 onwards, both new and recurrent TB cases 
have been classified as new/recurrent bacteriologically 
confirmed, clinically diagnosed and EPTB cases based on 
Xpert MTB/Rif results, the preferred first- line TB diag-
nostic test. The NTP also ensures these drug- susceptible 
patients with TB are prescribed a standardised treatment 
regimen of 6 months for new TB cases or 8 months for 
recurrent TB cases: doses are observed by a healthcare 
worker or community health worker for at least the first 
2 months of therapy.
Study population
The study population included: all PLHIV reported 
nationally in ART care at the end of each year; all PLHIV 
in ART care who were initiated on IPT annually and 
all patients annually diagnosed and notified with TB in 
Zimbabwe between 2000 and 2018.
Patient and public involvement
Patients or the public were not involved in the design, or 
conduct, or reporting, or dissemination of our research 
study.
Data variables and sources of data
National aggregate data on annual estimated numbers 
of PLHIV and annual numbers receiving ART were 
obtained from UNAIDS and WHO.21 28 Data on PLHIV 
estimates are generated annually using the Estimation 
and Projection Package and Spectrum software29 from 
UNAIDS based on primary collected data from census 
reports, antenatal clinic surveillance, population- based 
surveys and programme data. National population 
figures were obtained from the 2002 and 2012 national 
census reports with intercensus projections for the 
periods in between these reports and after 2012.19 30 31 
Data on annual numbers started on IPT were obtained 
from the Zimbabwe Demographic Health Information 
System version 2 (DHIS2). Finally, aggregate data on 
numbers notified each year with TB and further stratified 
by type and category of TB were obtained from the WHO 
website.32
Analysis and statistics
Data were analysed by plotting bar and line graphs of 
the various indicators over time from 2000 to 2018. ART 
coverage was calculated by dividing the annual total 
number of PLHIV receiving ART by the annual estimated 
number of PLHIV, instead of relying on ART coverages 
reported in annual UNAIDS or WHO reports since these 
were dependent on changing ART eligibility criteria over 
the years. IPT coverage rates were calculated as cumula-
tive annual numbers of PLHIV in ART care ever started 
on IPT divided by annual numbers of PLHIV receiving 
ART.
Annual TB case notification rates were calculated by 
dividing annual TB case notifications by annual national 
population figures to obtain case notifications per 100 000 
population. Changes in TB notification rates between 
2000 and 2018 were determined by comparing the 
highest TB case notification rates prior to national ART 
scale- up and the lowest annual TB case notification rates 
after roll- out of both ART (in 2004) and IPT (in 2012) 
using tests for proportions in Stata V.15.0 (StataCorp, 
College Station, Texas, USA). Levels of significance were 
set at 5%.
reSultS
Since the inception of ART in the public sector in 
2004, there was a substantial increase in the number 
and proportion of PLHIV initiated on ART from 8400 
(<1% ART coverage) in 2004 to over 1 million (88% ART 
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Figure 1 Numbers and coverage of PLHIV alive on ART in 
Zimbabwe, 2000–2018. ART coverage was calculated using 
the estimated HIV- infected population as the denominator 
from national projections obtained from the Joint United 
Nations Programme on HIV/AIDS Estimation and Projection 
Package and Spectrum software). ART, antiretroviral therapy; 
PLHIV, people living with the HIV.
Figure 2 Numbers on IPT and IPT coverage among PLHIV 
receiving ART in Zimbabwe, 2000–2018. IPT coverage was 
calculated using the cumulative annual numbers started on 
IPT as the numerator and cumulative annual numbers alive 
on ART as reported from the Zimbabwe DHIS2 reporting 
database. ART, antiretroviral therapy; DHIS, Demographic 
Health Information System; IPT, isoniazid preventive therapy; 
PLHIV, people living with the HIV.
Figure 3 Notification rates of all TB cases in Zimbabwe 
stratified by TB category, 2000–2018. PTB, pulmonary TB; 
TB, tuberculosis.
Figure 4 Notification rates of new TB cases in Zimbabwe 
stratified by type of TB, 2000–2018. PTB, pulmonary 
tuberculosis; TB, tuberculosis.
coverage) by the end of 2018 (figure 1). The number 
and proportion of PLHIV in ART care who were ever 
started on IPT increased from 98 (<1% coverage) in 2012 
to approximately 373 917 (33% coverage) by the end of 
2018 (figure 2).
All TB case notification rates increased between 2000 
and 2004 from a high of 446 cases/100 000 popula-
tion to a peak of 509 cases/100 000 population before 
declining steeply to 315 cases/100 000 population in 
2008 (figure 3). Following this, there was a brief increase 
in case notification rates to 372 cases/100 000 population 
before a steady decline to an all- time low of 173 cases/100 
000 population in 2018. A similar trend was observed for 
new TB cases which constituted the majority of all TB 
case notifications. Retreatment TB cases increased four-
fold between 2001 and 2004 from 13 cases/100 000 popu-
lation to 58 cases/100 000 population before declining 
to 20 cases/100 000 population in 2007. Thereafter, case 
notification rates increased to a plateau of 37 cases/100 
000 population in 2009 and 2010 prior to eventually 
declining steadily over time to 11 cases/100 000 popula-
tion by the end of 2018.
Clinically diagnosed PTB cases increased from 242 
cases/100 000 population in 2000 to an all- time peak of 
284 cases/100 000 population in 2002 and significantly 
declined although with intermittent increases observed 
in 2004 and 2009–2010 before reaching an all- time low 
of 63 cases/100 000 population in 2017 (figure 4). Bacte-
riologically confirmed PTB cases also increased from 126 
cases/100 000 population in 2000 to an all- time peak of 
137 cases/100 000 population in 2002 and later declined 
steadily to 79 cases/100 000 population in 2008. There-
after the rate of cases increased slightly before declining 
to an all- time low of 77 cases/100 000 population in 
2018. Extrapulmonary TB case notification rates declined 
steadily over time from 78 cases/100 000 population in 
2000 to their lowest of 16 cases/100 000 population in 
2018, with slight increases observed during 2001–2002 
and 2008–2009.
In figure 5, there was an observed decline in TB case 
notifications over the years with increasing ART and 
IPT coverage since their national roll- out in 2004 and 
2012, respectively. In table 1, there were overall signifi-
cant declines in all TB case notification rates between 
the highest recorded case notification rate prior to ART 
and IPT national roll- out in comparison with the lowest 
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Figure 5 Trends in notification rates of all TB cases versus 
ART and IPT coverage in Zimbabwe, 2000–2018. (ART 
coverage was calculated using the estimated HIV- infected 
population as the denominator from national projections 
obtained from the UNAIDS Estimation and Projection 
Package and Spectrum software. IPT coverage was 
calculated using the cumulative annual numbers started on 
IPT as the numerator and cumulative annual numbers alive 
on ART as reported from the Zimbabwe DHIS2 reporting 
database. ART, antiretroviral therapy; DHIS, Demographic 
Health Information System; TB, tuberculosis; UNAIDS, United 
nations Programme for HIV/AIDS.
Table 1 Comparisons of TB case notification rates, stratified by type and category prior to 2004 (at start of ART scale- up) and 
after ART roll- out and IPT roll- out (2012) in Zimbabwe
Type of TB
Highest 
notification rate 
(per 100 000) Year
Lowest 
notification rate 
(per 100 000) Year
Decrease 
(%) between 
highest and 
lowest P value*
All TB 510 2002 173 2018 66.1 <0.001
New TB 501 2002 159 2018 68.3 <0.001
  Bacteriologically confirmed PTB 137 2002 77 2018 43.8 0.143
  Clinically diagnosed PTB 284 2002 63 2017 77.8 <0.001
  Extrapulmonary TB 79 2002 16 2018 79.7 0.281
Previously treated TB 58 2004 11 2018 81.0 0.432
*Test of proportions comparing percentage decreases between the highest recorded case notification rate prior to ART and IPT scale- up and 
the lowest recorded case notification rate after ART roll- out (in 2004) and IPT roll- out (in 2012).
.ART, antiretroviral therapy; EPTB, extrapulmonary TB; IPT, isoniazid preventive therapy; PTB, pulmonary tuberculosis; TB, tuberculosis.
case notification rates after ART and IPT scale- up (66.1%, 
p<0.001). Similar significant declines in case notification 
rates were observed among those with new TB (68.3%, 
p<0.001) and among those with new clinically diagnosed 
PTB (77.8%, p<0.001).
DiSCuSSiOn
This study is a follow- on of a previous study showing the 
association between declines in TB case notifications 
from 2000 to 2013 and scale- up of ART in the public 
sector since its inception in 2004.16 In this current study, 
we assessed TB case notification rates for a further 5- year 
period up to 2018 after ART coverage had nearly doubled 
from nearly half of all estimated PLHIV to nearly 9 in 
10 PLHIV and after the National AIDS Programme had 
attained an IPT coverage of approximately one- third of 
patients receiving life- saving ART.
Our findings showed that these HIV- related interven-
tions (ART and IPT) were associated with significant 
declines in TB case notification rates between the highest 
and lowest reported case notification rates prior to and 
after the inception of ART and IPT in the public sector, 
respectively. These declines were observed for all TB cases 
combined and among those with new TB, in particular 
those with new clinically diagnosed PTB. In comparison 
to the previous study,16 there was a further percentage 
decline of TB case notification rates between the lowest 
recorded TB case notification rates reported then and 
those currently presented of 34%, 33%, 27%, 52% and 
59% for all forms of TB, new TB, new clinically diag-
nosed PTB, new EPTB and previously- treated TB cases, 
respectively.
These findings reaffirm the population impact of the 
pooled TB- protective effect of ART and IPT in a setting 
where TB is mainly HIV driven. This may also be coupled 
with implementation of intensified TB case finding 
among PLHIV to identify those eligible for IPT. Simul-
taneously, those needing TB treatment can be identified 
and treated, thus resulting in improved infection control 
in ART care settings where newly diagnosed TB cases are 
most prevalent.33 34
The further national gains in significantly increasing 
ART coverage towards the UNAIDS 90% ART coverage 
target by adopting an ‘HIV treat all’ approach in recent 
years have resulted in 64% of all estimated PLHIV in 
Zimbabwe being virally suppressed according to the last 
2015–2016 Zimbabwe Population HIV Impact Assess-
ment population- based survey.35 This has had a signif-
icant impact on the near threefold reduction in the 
estimated TB incidence in the population from 584 to 
221 cases/100 000 population between 2000 and 2017.4 36 
In line with our findings, a modelling exercise involving 
countries from sub- Saharan Africa also showed that the 
most notable decline in incidence of HIV- associated TB 
6 Takarinda KC, et al. BMJ Open 2020;10:e034721. doi:10.1136/bmjopen-2019-034721
Open access 
is seen when those diagnosed HIV positive are imme-
diately initiated on ART compared with delaying ART 
until 5 years after HIV seroconversion.37
Interestingly, the decline in TB case notifications 
which was higher in those with clinically diagnosed 
PTB has been sustained even though TB diagnosis has 
shifted from smear microscopy to Xpert MTB/Rif. The 
Xpert MTB/Rif assay is more sensitive in diagnosing TB 
in patients whose sputum smears are negative for acid- 
fast bacilli (which is more common among PLHIV),38 
and hence one might have anticipated an increase in 
numbers of TB cases detected rather than the observed 
decrease.
A recent modelling study showed that treatment of 
latent TB infection can result in a 14- fold decline in 
global TB incidence between 2013 and 2050 in compar-
ison to no treatment of latent TB infection.39 There-
fore, despite the observed and encouraging decline in 
TB case notifications, there are still opportunities for 
further declines given that IPT coverage is only approx-
imately one- third of PLHIV on ART. Uptake of IPT 
has slowed down because of resistance of some health 
workers who fear the development of isoniazid resis-
tance coupled with fears among patients given a few 
anecdotal reports of serious side effects among some 
patients taking this prophylactic treatment. Although 
IPT completion rates in Zimbabwe are higher than 
reported elsewhere, completion rates are still subop-
timal probably due to the increased pill burden of IPT 
over a 6–9 month duration.17 18 Improved completion 
rates may lead to a further decline in TB case notifica-
tion rates.
Zimbabwe’s planned national roll- out of a shorter 
regimen of TB preventive therapy (namely, a 12- week 
course of weekly rifapentine plus isoniazid—3HP) for 
children and adult PLHIV, following the feasibility 
phase roll- out in 10 pilot sites beginning in early 2020, 
can potentially lead to increased TB preventive therapy 
coverage. This may lead to further declines in TB inci-
dence among PLHIV in ART care. In comparison to the 
standard 6–9 months isoniazid monotherapy course, 
the 3HP prophylactic treatment course has been shown 
to have higher completion rates and a lower risk of 
adverse events, particularly hepatotoxicity.40
The major strength of this study is that national 
aggregate data that is routinely tracked as part of 
HIV/TB global response indicators were used, hence 
giving a comprehensive picture of what is prevailing 
in the country over time. The major limitation comes 
from the ecological design of the study which results 
in ‘the ecological fallacy’, whereby other factors that 
are attributed to the observed decline in TB case noti-
fications over time aside from ART and IPT are not 
accounted for.41 However, our findings are largely 
reliable as they are coherent with findings from well- 
conducted studies at the individual level using robust 
study methodologies.12–14 There are other limitations. 
TB case notifications may underestimate the true TB 
cases in Zimbabwe over time especially among PLHIV. 
Despite the use of GeneXpert, the test has been shown 
to have low sensitivity and specificity in settings were HIV 
prevalence is >30%.38 There may also have been missed 
TB cases through suboptimal TB screening among 
patients attending health facilities and leakages along 
the care cascade to sputum collection, submission for 
laboratory diagnosis, return of results and commence-
ment of TB treatment.42–44 Nevertheless, based on TB 
treatment coverages for Zimbabwe that were reported 
by WHO, these were relatively constant around 70%,32 
hence the observed annual TB case notification rates 
are probably standardised for undiagnosed TB cases.
In conclusion, this study shows continued declining 
trends of TB case notification rates that support the 
continued scale- up of ART and TB preventive therapy 
among PLHIV as key strategies for mitigating the dual 
burden of HIV/AIDS and TB in Zimbabwe and other 
regions with HIV- driven TB epidemics.
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